Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Immunodeficiency Viruses Clear all
Completed Phase 1 Interventional Results available

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

NCT05406583
View directory record Official record
Conditions
HIV
Interventions
Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life), Dolutegravir 5 mg Dispersible Tablets (single doses), Dolutegravir 5 mg Dispersible Tablets (chronic dose), Dolutegravir 0.5 mg/kg liquid suspension (starts at 2-5 days of life)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)

NCT00000701
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
2
States / cities
Miami, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

NCT00034866
View directory record Official record
Conditions
HIV Infections
Interventions
Protease inhibitor tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
50
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2005 · Synced Jun 25, 2026, 9:46 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

ETE Interventions in the Dental Setting

NCT05584501
View directory record Official record
Conditions
HIV Infections
Interventions
Care Navigator, Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Mechanisms of Lipodystrophy in HIV-Infected Pateints

NCT00457665
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir, Efavirenz
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Jun 25, 2026, 9:46 PM EDT
Completed No phase listed Observational

An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection

NCT01445145
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 30 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

NCT00131677
View directory record Official record
Conditions
HIV Infection
Interventions
tenofovir disoproxil fumarate, placebo
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 60 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir

NCT00486330
View directory record Official record
Conditions
HIV Infections
Interventions
Buprenorphine, Tipranavir and ritonavir
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Jun 25, 2026, 9:46 PM EDT
Terminated No phase listed Observational Results available

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

NCT01567722
View directory record Official record
Conditions
Lung Cancer, Lymphoma
Interventions
DNA analysis, RNA analysis, gene expression analysis, polymorphism analysis, biologic sample preservation procedure, flow cytometry, medical chart review
Genetic · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Treatment Program for Anemia in AIDS Patients

NCT00002022
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
R W Johnson Pharmaceutical Research Institute
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

NCT01749566
View directory record Official record
Conditions
HIV
Interventions
maraviroc
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

NCT00000902
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 21 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

NCT00000802
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone, Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 25, 2026, 9:46 PM EDT
Completed No phase listed Observational

The Second Multicenter Hemophilia Cohort Study

NCT00341705
View directory record Official record
Conditions
Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
2,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
39
States / cities
Tucson, Arizona • Davis, California • Orange, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 25, 2026, 9:46 PM EDT
Completed No phase listed Observational

Targeting Effective Analgesia in Clinics for HIV - Patient Cohort

NCT02525731
View directory record Official record
Conditions
HIV Infection, Pain, Drug Dependence
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

NCT00000801
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Cytarabine, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Not applicable Interventional Results available

HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics

NCT01312181
View directory record Official record
Conditions
Mental and Behavioral Disorders Due to Harmful Drug Use
Interventions
HealthCall and Motivational Interviewing, Motivational Interviewing (MI), HIV/AIDS health education
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)

NCT02330419
View directory record Official record
Conditions
Binge Drinking, HIV
Interventions
Placebo, Naltrexone, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers:, Behavioral survey measurements:, Dried Blood Spot (DSB) Testing for Phosphatidylethanol, Ecological Momentary Assessment
Drug · Behavioral · Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

NCT01410344
View directory record Official record
Conditions
Leukemia, Lymphoma, HIV
Interventions
Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Cyclophosphamide and Total Body Irradiation
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Vitamin B Therapy for Hyperlactatemia

NCT00031057
View directory record Official record
Conditions
HIV Infections
Interventions
Thiamine hydrochloride, Riboflavin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Jun 25, 2026, 9:46 PM EDT
Enrolling by invitation Not applicable Interventional

Promoting Aging and Thriving With HIV

NCT07192419
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Geriatric, Geriatric Assessment, HIV, HIV - Human Immunodeficiency Virus
Interventions
Promoting Aging and Thriving with HIV (PATH)-Implementation of a Tailored Geriatric Assessment and Management Strategy for HIV Care Settings
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Jun 25, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

NCT02519777
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo for maraviroc (MVC), Placebo for dolutegravir (DTG), Dolutegravir (DTG), Maraviroc (MVC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Jun 25, 2026, 9:46 PM EDT